SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending after its strong earnings report revealed robust demand for its AI platform and optimistic forward guidance, sparking widespread bullish excitement for significant upside, though some investors continue to debate its elevated valuation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending ahead of its highly anticipated earnings report, with investors keenly focused on a projected revenue surge and potential impact from Elon Musk's xAI merging with SpaceX. The community is sharply divided between expectations of a massive short squeeze fueled by undervaluation and critical AI infrastructure, and concerns over potential margin pressures and past earnings disappointments.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending intensely ahead of its expected earnings report, with community sentiment sharply divided between those who view the fintech giant as a deeply undervalued cash-generating machine poised for a turnaround, and others convinced it's a stagnant company facing relentless competition and further declines. Investors are eagerly awaiting clarity on management's strategy to combat perceived market share loss and capitalize on new growth initiatives amidst a prevailing bearish narrative despite low valuation metrics.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is trending following its latest earnings report, where robust overall performance was overshadowed by soft near-term revenue guidance, leading to a significant stock decline. The community is actively debating whether this represents an overreaction and a buying opportunity given the company's strong cash position and strategic role in the AI memory market, or if it signals valid execution risks.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is experiencing a massive rally driven by blowout earnings that significantly surpassed expectations and aggressive price target upgrades from analysts. The community is fiercely debating whether the surge is a justified "monster" run fueled by insatiable AI memory demand or an unsustainable "bubble" fueled by market manipulation.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending following a Q3 EPS miss attributed to tariff impacts on device margins, despite solid revenue growth and raised full-year guidance. The community is actively debating its high valuation and recent price drop against the company's market dominance, strategic AI-focused acquisitions, and potential for major government contracts, particularly the anticipated ICE bodycam mandate.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Atossa Therapeutics is trending intensely as a recently effective 1-for-15 reverse stock split has ignited widespread investor fury, with the community largely blaming CEO Steven Quay for significant losses and anticipating further dilutive actions despite faint bullish hopes for the pipeline.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics is highly active following a significant equity offering, viewed by some as strategic capital infusion from institutional investors and by others as dilution, occurring simultaneously with competitor Sanofi deprioritizing a rival therapy. The community is buzzing with speculation about a potential buyout and the company's promising radiopharmaceutical pipeline, driving notable volume and price target discussions amidst its role in the growing precision oncology sector.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending due to robust recent earnings, which surpassed expectations, fueled by overwhelming demand for high-capacity storage from AI data centers, with orders reportedly booked through 2026 and beyond. The community is buzzing about its exceptional performance and parabolic surge as a key AI infrastructure play, though some express caution regarding its rapid valuation increase.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

MiMedx Group is trending due to a proposed CMS rule that aims to drastically cut skin substitute reimbursement to curb industry fraud, sparking a polarized community debate between those who anticipate MDXG will gain significant market share with its clinically proven products and those who foresee substantial revenue losses from its previously high-average-selling-price offerings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CureVac (NASDAQ:CVAC) Reaches New 12-Month High - What's Next?

CureVac (NASDAQ:CVAC) Sets New 1-Year High - Here's What Happened...

CureVac (NASDAQ:CVAC) Reaches New 12-Month High - Should You Buy?

CureVac (NASDAQ:CVAC) Reaches New 12-Month High - Still a Buy...

CureVac (NASDAQ:CVAC) Hits New 12-Month Low - Here's Why

CureVac (NASDAQ:CVAC) Hits New 12-Month Low - Should You Sell...

CureVac (NASDAQ:CVAC) Shares Gap Down - Time to Sell?

CureVac (NASDAQ:CVAC) Shares Gap Down - Time to Sell...

CureVac (NASDAQ:CVAC) Trading Down 9.9% - Time to Sell?

CureVac (NASDAQ:CVAC) Shares Down 9.9% - Here's Why...

CureVac N.V. (NASDAQ:CVAC) Receives Average Recommendation of "Hold" from Analysts

CureVac N.V. (NASDAQ:CVAC - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One...

CureVac Enters Oversold Territory (CVAC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC

Carlson Capital L.P. bought a new position in CureVac N.V. (NASDAQ:CVAC - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange...

CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Here's What Happened

CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Still a Buy...

Company News for Nov 25, 2025

Companies In The News Are: CVAC, CAAP, NVO, BABA.

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

Current Price	$4.66
Prev Close	$4.67
Open	$4.57
Dividend Yield	0.00%
50-Day Moving Average	$4.77
Beta	0.95
Avg. Volume	134,876.75
PE Ratio	6.48

52-Week High	$5.72
52-Week Low	$2.48
Market Capitalization	$1.05B
EPS (Annual)	$0.7819
Price to Book	1.02
Revenue Per Employee	$588,910.74
Enterprise Value/EBITDA	N/A

CVAC
CureVac N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CVAC News

CVACCureVac N.V.